PM 1003
Alternative Names: PM-1003Latest Information Update: 10 Feb 2025
At a glance
- Originator Biotheus
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 03 Feb 2025 Biotheus has been acquired by BioNTech
- 20 Oct 2023 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 05 Apr 2022 Phase-I clinical trials in Solid tumours in China (Parenteral) (Biotheus pipeline, April 2022)